PP
LAB icon

PDT Partners’s Standard BioTools LAB Stock Holding History

PDT Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-149,136
Closed -$585K – 1024
2021
Q4 		$585K Buy
149,136
+21,236
+17% +$99.4K 0.04% 490
2021
Q3 		$843K Sell
127,900
-68,728
-35% -$452K 0.06% 380
2021
Q2 		$1.21M Sell
196,628
-286,890
-59% -$1.53M 0.08% 341
2021
Q1 		$2.19M Buy
483,518
+408,243
+542% +$2.24M 0.16% 254
2020
Q4 		$452K Sell
75,275
-141,791
-65% -$932K 0.03% 467
2020
Q3 		$1.61M Buy
+217,066
New +$1.5M 0.11% 242
2019
Q3 		– Sell
-74,838
Closed -$922K – 466
2019
Q2 		$922K Buy
74,838
+38
+0.1% +$484 0.05% 260
2019
Q1 		$994K Buy
74,800
+40,150
+116% +$423K 0.06% 260
2018
Q4 		$299K Buy
34,650
+17,350
+100% +$135K 0.02% 372
2018
Q3 		$130K Sell
17,300
-10,301
-37% -$73.2K 0.01% 452
2018
Q2 		$165K Sell
27,601
-7,717
-22% -$44K 0.01% 481
2018
Q1 		$206K Buy
35,318
+4,802
+16% +$31.5K 0.01% 525
2017
Q4 		$180K Buy
30,516
+2,464
+9% +$13.5K 0.01% 513
2017
Q3 		$141K Buy
28,052
+752
+3% +$3.16K ﹤0.01% 501
2017
Q2 		$110K Buy
27,300
+9,800
+56% +$46.5K ﹤0.01% 502
2017
Q1 		$100K Sell
17,500
-24,200
-58% -$153K 0.01% 461
2016
Q4 		$304K Buy
41,700
+11,500
+38% +$72.2K 0.02% 434
2016
Q3 		$242K Sell
30,200
-15,400
-34% -$141K 0.01% 425
2016
Q2 		$412K Buy
+45,600
New +$429K 0.03% 351
2015
Q3 		– Sell
-11,574
Closed -$280K – 1428
2015
Q2 		$280K Buy
+11,574
New +$365K 0.01% 1152
2013
Q3 		– Sell
-13,457
Closed -$235K – 1609
2013
Q2 		$235K Buy
+13,457
New +$236K 0.01% 1326

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PDT Partners's LAB Position: Q1 2022 in Review

PDT Partners sold out of Standard BioTools (LAB) in Q1 2022, closing a stake of 149,136 shares — an estimated $585K sold.

PDT Partners first reported a position in LAB in Q2 2013 and held it in 21 quarters. The position peaked at $2.19M in Q1 2021. 109 funds tracked by Wall St. Rank hold LAB as of Q1 2022.

  • PDT Partners reported no remaining Standard BioTools position as of Q1 2022 after selling out during the quarter.
  • PDT Partners sold 149,136 Standard BioTools shares in Q1 2022, an estimated $585K.
  • PDT Partners first reported a position in Standard BioTools in Q2 2013 and held it in 21 quarters.
  • PDT Partners's Standard BioTools position peaked at $2.19M in Q1 2021.
  • 109 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2022.

Based on PDT Partners's 13F filing for Q1 2022, filed 16 May 2022.